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Abstract: Sphingosine kinase (SK) catalyses the formation of sphingosine 1-phosphate (S1P), which
acts as a key regulator of inflammatory and fibrotic reactions, mainly via S1P receptor activation.
Here, we show that in the human renal proximal tubular epithelial cell line HK2, the profibrotic
mediator transforming growth factor β (TGFβ) induces SK-1 mRNA and protein expression, and
in parallel, it also upregulates the expression of the fibrotic markers connective tissue growth factor
(CTGF) and fibronectin. Stable downregulation of SK-1 by RNAi resulted in the increased expression
of CTGF, suggesting a suppressive effect of SK-1-derived intracellular S1P in the fibrotic process,
which is lost when SK-1 is downregulated. In a further approach, the S1P transporter Spns2, which
is known to export S1P and thereby reduces intracellular S1P levels, was stably downregulated in
HK2 cells by RNAi. This treatment decreased TGFβ-induced CTGF and fibronectin expression,
and it abolished the strong induction of the monocyte chemotactic protein 1 (MCP-1) by the
pro-inflammatory cytokines tumor necrosis factor (TNF)α and interleukin (IL)-1β. Moreover, it
enhanced the expression of aquaporin 1, which is an important water channel that is expressed in
the proximal tubules, and reverted aquaporin 1 downregulation induced by IL-1β/TNFα. On the
other hand, overexpression of a Spns2-GFP construct increased S1P secretion and it resulted in
enhanced TGFβ-induced CTGF expression. In summary, our data demonstrate that in human renal
proximal tubular epithelial cells, SK-1 downregulation accelerates an inflammatory and fibrotic
reaction, whereas Spns2 downregulation has an opposite effect. We conclude that Spns2 represents a
promising new target for the treatment of tubulointerstitial inflammation and fibrosis.
Keywords: human renal proximal tubular epithelial cells; fibrosis; inflammation; sphingosine
1-phosphate; sphingosine kinase 1; spinster homology protein 2 (Spns2); CTGF; aquaporin 1
1. Introduction
Sphingosine 1-phosphate (S1P) is a central sphingolipid molecule that regulates a variety
of important cellular responses, including proliferation and migration, and it also modulates
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inflammatory and fibrotic responses depending on its site of action [1–3]. Most of its reported
actions are mediated by five identified high-affinity S1P receptor subtypes, which are denoted as
S1P1−5 [4]. The receptor subtypes differentially couple to multiple G proteins, and thereby activate
a complex network of signal transduction events and cellular outcomes. Alternatively, S1P can act
as an intracellular second messenger and activate intracellular targets, which, however, are still
poorly defined and controversial. Among these, the tumor necrosis factor (TNF) receptor-associated
factor 2 (TRAF2) was shown to directly bind S1P, which activates its ubiquitin E3 ligase activity
and leads to nuclear factor κB (NFκB) activation [5]. In addition, direct binding of S1P to nuclear
histone deacetylase (HDAC)1 and HDAC2 [6], mitochondrial prohibitin-2 [7], and cytosolic ceramide
synthase-2 [8] was reported.
S1P is generated by sphingosine kinases (SK), of which two subtypes SK-1 and SK-2 and several
splice variants exist [9]. Both enzymes are ubiquitously expressed, but they differ slightly in their
biochemical and enzymatic properties, and most importantly in subcellular localizations [9]. However,
the physiological or pathophysiological function of these two enzymes, whether differential or similar,
is currently not fully understood. Whereas, many reports have shown a role for SK-1 in the cell
proliferation and migration of multiple cell types, the role of SK-2 is still controversial, ranging from
pro-apoptotic [10], anti-proliferative [11,12], to even pro-proliferative [13] and pro-migratory [14].
As S1P is generated intracellularly (iS1P), it must be exported out of the cell to act as a receptor
ligand. It has become clear that the transporter spinster homology protein 2 (Spns2) is mainly
responsible for the secretion of S1P from many cell types [15]. Spns2 belongs to the major facilitator
superfamily (MFS) of atypical solute carriers (SLC), and its gene deficiency in mice leads to a 40%
reduction of plasma S1P levels [16] due to the lack of S1P release from vascular endothelial cells. Yet,
in erythrocytes and platelets, Spns2 knockout had no effect on S1P secretion suggesting that other
carriers exist in these cells, most notably the ABCA7 and ABCC1 transporters [17]. Spns2 deficient
mice develop lymphopenia due to the reduced egress of mature T cells from the thymus to the blood,
and further develop a profound hearing loss due to a defect in endocochlear potential and progressive
degeneration of sensory hair cells in the organ of Corti [18]. The pathophysiological relevance of
Spns2-mediated S1P secretion was recently reported by Donoviel et al. [19] who used Spns2-deficient
mice in various disease models including airway inflammation and hypersensitivity, dextran sulfate
sodium-induced colitis, collagen-induced arthritis, and experimental autoimmune encephalomyelitis,
and described a strong reduction of disease parameters. Obviously, retaining S1P inside the cells has
a protective effect in all of these inflammation associated models. So far, not much is known about
the regulation of Spns2 expression or posttranslational modifications. Fu and colleagues recently
reported that in human lung microvascular endothelial cells, hepatocyte growth factor can stimulate
PI3K/Akt-dependent phosphorylation of Spns2 at a serine residue and trigger redistribution from a
diffuse cytosolic location to the cell periphery, where it co-localizes with actin in lamellipodia [20].
Renal proximal tubular epithelial cells play an important role in tubulointerstitial inflammation
and fibrosis. Proteinuria and protein overload to the tubular system, which develops in several
forms of chronic kidney diseases, is considered to be a key factor that triggers the activation of
proximal tubular epithelial cells to produce and/or secrete into the interstitium various inflammatory
mediators, including interleukin (IL)-6, IL-8, monocyte chemoattractant peptide 1 (MCP-1/CCL2),
RANTES/CCL5, and the intercellular adhesion molecule 1, but also fibrotic molecules such as
connective tissue growth factor (CTGF) and fibronectin [21]. Many studies have shown that under
cell culture conditions, proximal tubular epithelial cells are activated by the pro-fibrotic mediator
transforming growth factor (TGF)β to undergo epithelial-mesenchymal transition (EMT) which
is demonstrated by reduced expression of epithelial markers such as cytokeratin and E-cadherin,
and increased the expression of mesenchymal markers, such as α-smooth muscle actin and vimentin.
This suggests that tubular epithelial cells may also transform in vivo to myofibroblasts during
fibrosis [22]. However, evidence for EMT in vivo in tubulointerstitial fibrosis is still controversial, and
convincing evidence is still missing [23]. Proximal tubular epithelial cells also express a multitude
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of transporters that are important for the physiological function of the renal tubular system, i.e.,
reabsorption of solutes, peptides, and ions. In addition, various aquaporin (AQP) water channels are
expressed along the tubular system and mediate water reuptake [24]. Under pathophysiological
conditions, such as acute kidney injury, sepsis, and chronic inflammatory kidney diseases, the
expression of AQPs is often altered, leading to either polyuria or to increased water reabsorption and
edema formation. Notably, AQP-1, -2 and -3 were reported to be downregulated in experimental
models of acute renal injury, and treatment strategies that reduced acute renal injury and polyuria also
normalized AQPs expression [25]. However, the detailed mechanisms that especially regulate AQP1
are still unclear.
In this study, we investigated the effect of SK-1 knockdown (kd), which reduces iS1P, and of
Spns2kd, which increases iS1P, on the fibrotic and the inflammatory reaction in the human renal
proximal tubular epithelial cell line HK2. We show that, in HK2 cells, the profibrotic cytokine TGFβ
upregulates CTGF and fibronectin expression, and in parallel also SK-1 expression. Upon SK-1
knockdown, CTGF was further increased, thus supporting our previous hypothesis based on data with
other renal cell types that iS1P has a suppressive effect on fibrotic processes [1]. Spns2 knockdown
was anti-fibrotic and anti-inflammatory, as it decreased TGFβ-stimulated expression of CTGF and
fibronectin as well as expression of the pro-inflammatory chemokine MCP-1. These data underline
the promise of Spns2 as an attractive pharmacological target to prevent secretion of iS1P and thereby
dampen inflammatory and fibrotic responses, such as those seen in tubulointerstitial nephritis.
2. Results
To investigate the contribution of cellular S1P to tubulointerstitial inflammation and fibrosis, we
used the human renal proximal tubular epithelial cell line HK2, which represents an important cell
type that is involved in tubulointerstitial nephritis that are characterized by both an inflammatory
and a fibrotic phase. In a first step, we treated HK2 cells with the pro-fibrotic mediator TGFβ and the
pro-inflammatory cytokines TNFα and IL-1β to see whether the SK-1 protein expression is affected
under fibrotic or inflammatory conditions. As seen in Figure 1A,B, TGFβ stimulated a time-dependent
upregulation of SK-1 protein expression with a maximal effect after 24 h of treatment. Since TGFβ is
well known to stimulate the Smad signalling cascade, which mediates gene transcription of various
pro-fibrotic factors including CTGF and fibronectin, we analysed first whether the Smad signalling
cascade is activated by TGFβ in HK2 cells by measuring Smad2 phosphorylation. Phospho-Smad2
was strongly increased at 4 h, and it remained high over 24 h (Figure 1A,C). In addition, CTGF protein
was also upregulated by TGFβ in a time-dependent manner (Figure 1A,D,E). A similar upregulation
was also detected for fibronectin (Figure 1A,F). The increased protein expressions of SK-1, CTGF, and
fibronectin were preceded by increased mRNA expressions of SK-1 (Figure 2A), CTGF (Figure 2B),
and fibronectin (Figure 2C).
As we had previously shown that in human glomerular podocytes, TGFβ-induced SK-1 acts
as a brake in CTGF expression [26], we further studied here whether the same regulation occurs
in HK2 cells. For this, a stable SK-1kd HK2 cell line was generated by the lentiviral transduction
method. This cell line showed a 75–80% reduction of SK-1 protein (Figure 3A,B) and mRNA expression
(Figure 3E). SK-1kd HK2 cells showed an increased basal CTGF expression and secretion (Figure 3C,D),
which, upon TGFβ stimulation, was even further increased when compared to TGFβ-stimulated
control HK2 cells. A similar effect was also seen for CTGF mRNA expression (Figure 3F). To test
whether intracellular S1P indeed suppresses CTGF production, we used a caged-S1P, which does not
bind S1P receptors, but is taken up by cells and upon illumination cleaves off the protective group
generating active intracellular S1P [27,28]. When HK2 cells were treated with this caged-S1P, CTGF
expression was concentration-dependently reduced (Figure 4A, left panel). As HK2 cells express
several of the S1P receptors in the order S1P1 > S1P5 > S1P2 >> S1P3 (no S1P4), as measured by qPCR
analysis, we also tested whether extracellular S1P has an effect on CTGF expression. However, S1P,
used up to 2 µM, did not affect CTGF expression in these cells (Figure 4A, right panel), which contrasts
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the finding in other cell types, such as renal mesangial cells [29] and podocytes [26], which responded
to extracellular S1P (eS1P) with increased CTGF production. Notably, eS1P and a series of more
selective S1P receptor agonists, including BAF312 (S1P1 + 5), CYM5442 (S1P1), CYM5520 (S1P2), and
CYM5541 (S1P3), were all unable to activate the extracellular signal-regulated kinase (ERK) signalling
cascade (Figure 4B). These data suggest that, although various S1P receptors are expressed on the
mRNA level, their functionality in HK2 cells is still unclear.
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Figure 1. Effect of transforming growth factor β (TGFβ2) on SK-1, phospho-Smad2, connective
tissue growth factor (CTGF), and fibronectin expression in HK2 cells. (A) HK2 cells were taken
unstimulated (−) or stimulated with 5 ng/mL of TGFβ2 for the indicated time periods up to 24 h.
Thereafter, cell lysates were prepared and equal amounts of proteins were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a nitrocellulose membrane
and subjected to Western blotting using antibodies against SK-1 (1:2000 dilution), glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (1:2000), phospho-Smad2 (1:1000), CTGF (1:500), and fibronectin
(1:500). To detect secreted CTGF, equal volumes of supernatants of stimulated cells were taken for
protein precipitation by trichloroacetic acid (TCA) and were then analysed the same way as described
for lysates using the CTGF antibody. Band intensities were evaluated by a LICORR imaging system.
Data in (B–F) show the evaluated respective bands. Results are expressed as fold increase and are
means ± S.D. (n = 3); * p < 0.05, ** p < 0.01, *** p < 0.001 considered statistically significant when
compared to the respective control values.
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± S.D. (n = 3), ** p < 0.01, *** p < 0.001 considered to be s atistically significant whe compared to the
respective control values.
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Figure 3. Effect of SK-1 knockdown on TGFβ-stimulated CTGF expression in HK2 cells. (A–D):
HK2 cells stably transduced with either a lentiviral control vector (ctrl) or a SK-1 shRNA construct
(shSK-1) were stimulated for 24 h with either vehicle (−) or 5 ng/mL of TGFβ2. Thereafter, cell
lysates were taken for protein extraction and equal amounts of proteins were separated by SDS-PAGE,
transferred to a nitrocellulose membrane, and then subjected to Western blotting using antibodies
against SK-1, recognizing both splice variants SK-1a and -1b, CTGF, and GAPDH. To detect secreted
CTGF, supernatants of stimulated cells were taken for protein precipitation by TCA and then analysed
the same way, as described for lysates using the CTGF antibody. Band intensities were evaluated using
a LICORR imaging system. (E,F): cells were stimulated for 4 h with either vehicle (−) or 5 ng/mL
TGFβ2. Thereafter, RNA was extracted and taken for qPCR analysis using primers for SK-1 (E) and
CTGF (F). Results are expressed as fold increase when compared to the vehicle-treated controls and are
means ± S.D. (n = 3); * p < 0.05, *** p < 0.001 considered to be statistically significant when compared to
the vehicle-treated control values; # p < 0.05, ## p < 0.01, ### p < 0.001 as compared to the TGFβ-treated
control values; § p < 0.05 as compared to the vehicle-treated shSK-1 values.
s our data suggest that iS1P, which derives fro SK-1, has a suppressive effect on T F
expression, e tested this possibility using an alternative strategy, i.e., by increasing iS1P by
do nregulating the S1P transporter Spns2. Spns2 is expressed in HK2 cells and lentiviral transduction
of an Spns2 directed shRNA construct resulted in a stable Spns2kd HK2 cell line, which showed an
approx. 60% reduction of Spns2 mRNA (Figure 5A) and protein (Figure 5B) when compared to control
vector transduced cells. To determine the accumulation of S1P upon Spns2kd, an indirect reporter
assay was used. In this assay, sonicated cell lysates were used to subsequently stimulate S1P3 receptor
overexpressing CHO cells for 10 min and were analysed for ERK phosphorylation as an early read-out
of receptor activation. As seen in Figure 5C, Spns2kd increased cellular sphingoid phosphates content
as compared to control cells. Since the S1P3 receptor binds both S1P and dihydro-S1P, this assay cannot
discriminate between the two species [30]. Therefore, the cellular levels of S1P and dihydro-S1P were
quantitatively analysed by mass spectrometry. When compared to control cells, in Spns2kd cells only
dihydro-S1P, which is generated directly by de-novo synthesis from dihydro-sphingosine upo SK
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action, but not S1P, was enhanced (Figure 5C inset). Notably, both of the species are transported
by Spns2 [31] and show a similar S1P receptor activation profile [30]. Treatment of the Spns2kd
cell line with TGFβ revealed a strongly reduced expression of CTGF protein (Figure 6A,B) and
fibronectin protein (Figure 6A,C). Although the mRNA expression of CTGF was also reduced by
Spns2kd (Figure 6D), phospho-Smad2 was not affected in TGFβ-stimulated Spns2kd cells as compared
to TGFβ-stimulated control cells (Figure 6A, lowest panel). This suggests that the downregulation of
CTGF gene transcription occurs independent of Smad activation.
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Figure 4. Effect of caged-S1P and extracellular S1P (eS1P) on CTGF expression and extracellular
signal-regulated kinase (ERK) phosphorylation in HK2 cells. (A) Left panel: HK2 cells were treated
with either vehicle (−), 1, 2 or 10 µM of caged S1P for 20 min for cellular uptake. Then cells were washed
with PBS and illuminated f r 3 s with light of 366 nm wavelength and further incubated for 24 h in
DMEM. Right panel: Cells wer stimulated for 24 h with 0.1, 1, or 2 µM S1P. (B) Cells were stimulated
for 10 min with ve icle (−) or the diff rent S1PR ag nists: S1P1 + 5 agonist BAF312 (BAF, 1 µM), S1P1
agonist CYM5442 (5442, 1 µM), S1P2 agonist CYM5520 (5520, 10 µM), S1P3 agonist CYM5541 (5541, 2
µM), and S1P (2 µM). Thereafter, cell lysates or supernatants were taken for SDS-PAGE, transferred
to a nitrocellulose membrane, and then subjected to Western bl tting using antibodies against CTGF
(A), phospho-ERK1/2 (B), and GAPDH (B). Bands were valuated and result a e depicted a fold
increas and are means ± S.D. (n = 3); * p < 0.05, ** p < 0.01 considered to be statistically significant
when compared to untreated controls.
Since HK2 cells are known to produce a variety of pro-inflammatory cytokines and chemokines
under inflammatory conditions, we further investigated whether Spns2kd can affect this inflammatory
response. MCP-1/CCL2 is well known to be strongly induced by proinflammatory stimuli [32,33], and
it is considered to be a useful urinary biomarker for tubular inflammation and interstitial fibrosis [34].
In control HK2 cells, MCP-1 mRNA (Figure 7A) and protein expression (Figure 7B) were strongly
induced by a combined TNFα plus IL-1β treatment, and this effect was abolished by Spns2kd
(Figure 7A,B). In SK-1kd cells, the opposite effect was seen, i.e., MCP-1 protein showed enhanced
expression when compared to the control cells (Figure 7C).
In a further approach, we overexpressed green fluorescence protein (GFP)-fused Spns2 in HK2
cells. Characterization of these transiently overexpressing cells by confocal microscopy revealed clear
plasma membrane localization, as expected for the S1P-transporter (Figure 8A). Spns2 overexpressing
cells also secreted more sphingoid phosphates, as determined by an indirect reporter assay (Figure 8B).
Furthermore, basal and TGFβ-induced CTGF secretion was enhanced (Figure 8C,D).
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Figure 5. Characterization of Spns2 knockdown HK2 cells. HK2 cells stably transduced with either
a lentiviral control construct (ctrl) or a Spns2 shRNA construct (shSpns2) were taken for RNA and
protein extraction and analyzed by quantitative PCR and Western blotting for Spns2 mRNA (A)
and protein expression (B). Cell monolayers of either control cells (Ctrl) or Spns2 knockdown cells
(shSpns2) were lysed in PBS/high BSA and were taken for stimulation of S1P3-CHO cells (10 min) as
described in the Methods Section, and ERK phosphorylation was determined by Western blotting (C).
In parallel, cell monolayers were taken for lipid extraction and mass spectrometric quantification of
sphingolipids. dhS1P (in pg/106 cells) was the only sphingoid phosphate increased in shSpns2 (C,
inset). Band intensities were evaluated using a LICORR imaging system. Results are expressed as
% of control transduced cells and are means ± S.D. (n = 4–5 (A,B), n = 8 (C)); * p < 0.05, ** p < 0.01,
*** p < 0.001 considered to be statistically significant when compared to the control vector samples.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 18 
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Figure 6. Effect of Spns2 knockdown on TGFβ-induced CTGF and fibronectin expression and Smad2
phosphorylation in HK2 cells. Control transduced cells (ctrl) and Spns2 knockdown cells (shSpns2)
were stimulated for 20 h with either vehicle (−) or 5 ng/mL of TGFβ2. Thereafter, cell monolayers
and supernatants were taken for protein extraction or precipitation, proteins were separated by
SDS-PAGE, transferred to a nitrocellulose membrane, and then subjected to Western blotting using
antibodies against CTGF (A), fibronectin (A), phospho-Smad2 (A), or α-tubulin (A). Band intensities
were evaluated using a LICORR imaging system. Data in (B,C) show the evaluated respective bands
from the Western blots, are expressed as fold increase, and are means ± S.D. (n = 3). (D) Cells were
stimulated for 20 h with either vehicle (−) or TGFβ2 and RNA was extracted and taken for qPCR
analysis using primers for CTGF. Results in D are expressed as fold increase and are means ± S.D.
(n = 3); * p < 0.05, ** p < 0.01, *** p < 0.001 considered to be statistically significant when compared to
the vehicle-treated control cells; # p < 0.05, ## p < 0.01 as compared to the TGFβ-treated ctrl cells.
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Figure 7. Effect of Spns2 knockdown and SK-1 knockdown on tumor necrosis factor
(TNF)α/interleukin (IL)-1β-stimulated MCP-1/CCL2 mRNA and protein expression in HK2 cells.
Control transduced cells (ctrl), Spns2 knockdown cells (shSpns2, A,B), or SK-1 knockdown cells (shSK-1,
C) were stimulated for 20 h (A,B) or 24 h (C) with either vehicle or TNFα (1 nM) plus IL-1β (1 nM).
Thereafter, either RNA was extracted and taken for qPCR analysis using primers of MCP-1 (A) or
supernatants were collected and taken for a MCP-1 ELISA (B,C). Results in A are expressed as fold
increase as compared to the vehicle-treated control cells and are means ± S.D. (n = 3). Results in
(B,C) are expressed as pg/mL MCP-1 in the supernatant and are means ± S.D. (n = 3). * p < 0.05,
*** p < 0.001 considered to be statistically significant when compared to the vehicle-treated control
cells; ### p < 0.001 as compared to the TNF/IL-1 stimulated ctrl cells; §§§ p < 0.001 compared to the
vehicle-treated shSK-1 cells.
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We next analyzed whether the main AQP expressed in the proximal tubular cells, i.e., AQP1,
is affected by Spns2kd/S1P. As seen in Figure 9A, AQP1 mRNA expression in HK2 cells was
downregulated by a combined TNFα plus IL-1β treatment. Spns2kd in HK2 cells resulted in increased
basal AQP1 mRNA and the TNFα/IL-1β-mediated downregulation of AQP1 was normalized,
suggesting, for the first time, a regulation of AQP1 by the S1P signalling system. A similar regulation
was also seen on the protein level detected by Western blotting. AQP1 has been described as a
28 kDa protein that upon glycosylation appears in two higher molecular forms of 38–50 kDa and
55–70 kDa [35–37]. In HK2 cells, AQP1 ran as exclusively glycosylated forms of 38 kDa and 70 kDa
with no detectable unglycosylated form (Figure 9B). Upon TNFα/IL-1β stimulation, the expression
of the 38 kDa and 70 kDa AQP forms were partially downregulated. Notably, in Spns2kd cells, basal
expression of the 70 kDa AQP1 was already enhanced and the downregulation by TNFα/IL-1β was
less efficient (Figure 9B,C).
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CTGF and fibronectin expression (Figure 6), which are important pro-fibrotic mediators and fibrotic 
markers of tubulointerstitial fibrosis [38]. It suggests that iS1P, which is supposed to accumulate 
when Spns2 expression is reduced, can counter-regulate CTGF expression, a hypothesis that is 
further supported by our finding that caged-S1P, which upon illumination liberates active S1P in the 
intracellular space, reduces CTGF (Figure 4A). These data are in line with our previous study in 
glomerular podocytes, which were also protected by iS1P from CTGF expression [26]. However, in 
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Figure 9. Effect of Spns2 knockdown on aquaporin 1 mRNA and protein expression in HK2 cells.
Control (ctrl) or Spns2 knockdown cells (shSpns2) were stimulated for 20 h with vehicle (−) or TNFα
(1 nM) plus IL-1β (1 nM). Thereafter, cells were taken for RNA extraction and subsequent qPCR
analysis of aquaporin (AQP1) (A), or for protein extraction and Western blotting using antibodies
against AQP-1 and GAPDH (B). The 70 kDa band of AQP1 was densitometrically evaluated (C).
In B, mouse mesangial cells (mMC) were used as a standard for unglycosylated (28 kDa) and low
glycosylated (38 kDa) AQP1. Results in A and C are expressed as fold increase as compared to controls
and are means ± S.D. (n = 3–4); ** p < 0.01, *** p < 0.001 considered to be statistically significant when
compared to the vehicle-treated ctrl cells, ## p < 0.01 as compared to the TNFα/IL-1β-treated ctrl cells.
Results in B show one representative blot with duplicate samples.
3. Discussion
In this study, we show for the first time that the S1P transporter Spns2 is expressed in renal
proximal tubular epithelial cells where it regulates a fibrotic reaction (Figure 5A,B). Our data
demonstrate that stable downregulation of Spns2 in HK2 cells protects these cells from TGFβ-induced
CTGF and fibronectin expression (Figure 6), which are important pro-fibrotic mediators and fibrotic
markers of tubulointerstitial fibrosis [38]. It suggests that iS1P, which is supposed to accumulate
when Spns2 expression is reduced, can counter-regulate CTGF expression, a hypothesis that is
further supported by our finding that caged-S1P, which upon illumination liberates active S1P
in the intracellular space, reduces CTGF (Figure 4A). These data are in line with our previous
study in glomerular podocytes, which were also protected by iS1P from CTGF expression [26].
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However, in podocytes, we identified a profibrotic effect of eS1P, as it upregulated CTGF expression.
This pro-fibrotic effect of eS1P could not be seen in tubular epithelial cells since eS1P could neither
upregulate CTGF expression (Figure 4A) nor activate early ERK signalling (Figure 4B). We therefore
hypothesize that S1P receptors, although expressed on the mRNA level, are not functional, maybe
because they are stably desensitized or are not localized on the cell surface. Notably, proximal tubular
epithelial cells are highly polarized cells and the expression pattern of receptor and transporters in vivo
may be unique at either the apical or basolateral side. Furthermore, it is possible that secreted S1P acts
in a paracrine manner on other cell types, such as fibroblasts/myofibroblasts in the interstitium, to
promote the fibrotic events that are contributing to tubulointerstitial fibrosis.
Another factor that is strongly downregulated by Spns2kd in HK2 cells in our study is
MCP-1/CCL2 (Figure 7). MCP-1/CCL2 is highly induced by inflammatory stimuli, like TNFα and
IL-1β [39]. It is not only produced and secreted by monocytes and macrophages, but also by various
renal cell types, such as glomerular mesangial cells, podocytes, and tubular epithelial cells [40–42].
Moreover, it is considered to be crucial for recruiting monocytes/macrophages to the kidney in many
forms of inflammatory kidney diseases, thereby driving the progression of renal injury. Thus, not
surprisingly, urinary MCP-1 has been suggested as a diagnostic marker for progressive renal injury
in diabetic nephropathy [34,42], and pharmacological targeting of MCP-1 and its receptor CCR2
has been proposed as a novel approach to treat diabetic kidney disease [43,44]. Our data show
that in SK-1kd cells, which have reduced iS1P levels, MCP-1 synthesis (Figure 7C), but also CTGF
expression (Figure 3A) are enhanced, suggesting increased inflammation and fibrosis. These data are in
agreement with previous reports on SK-1 knockout mice or mice that were treated with a selective SK-1
inhibitor, showing enhanced UUO-induced tubulointerstitial fibrosis [45] and streptozotocin-induced
glomerulosclerosis by the loss of SK-1 activity [26].
In Spns2kd cells, MCP-1 induction is not only abolished on the protein level but also on
the mRNA level, indicating that accumulating iS1P suppresses gene transcription of MCP-1. In
this regard, the regulation of MCP-1 by S1P is still controversial. Chen et al. [46] showed that in
human endothelial cells in culture, the downregulation of SK-1 using siRNA reduced TNFα-induced
MCP-1 expression, suggesting a positive regulatory role of SK-1-derived S1P in MCP-1 expression.
In agreement with these findings, a previous study on mouse peritoneal macrophages also showed
that biglycan-triggered MCP-1/CCL2 production was strongly reduced in macrophages that were
isolated from SK-1 knockout mice [47]. Similarly, in the lung cancer cell line A549, thrombin stimulated
upregulation of SK-1 and MCP-1 expression, and downregulation of SK-1 using siRNA abolished
thrombin-induced MCP-1 expression [48]. However, in a rat model of albumin overload-induced
nephropathy, which typically showed increased MCP-1 production in the kidney, the treatment of rats
with the functional S1P1 antagonist FTY720 decreased MCP-1 production and mitigated pathological
features [49]. The mechanism of FTY720 mediated MCP-1 downregulation is still unclear since FTY720
can act in a dual manner, either as a short-term unselective S1P receptor agonist, or, when being
applied in a sustained manner, as a selective functional antagonist of S1P1.
Gene transcription of MCP-1 is strongly driven by the transcription factors NFκB and Sp1, and the
functional binding sites for these transcription factors have been identified in the promoter sequence
of MCP-1 [50]. Whether iS1P affects MCP-1 transcription by interfering with one of these transcription
factors remains to be determined. Especially, the role of S1P in inflammation is still a matter of debate.
At least some studies have suggested a rather pro-inflammatory role of iS1P by activating NFκB,
possibly through direct TRAF2 activation [5,47]. On the other hand, in other studies, macrophages that
were isolated from myeloid SK-1/SK-2 double knockout mice showed no change of LPS-triggered
NFκB activation or cytokine production, nor a change in proliferation or apoptosis, but instead showed
increased autophagic markers [51]. In addition, Etemadi et al. [52] showed that neither TRAF2 nor
SK-1 are required for TNFα-mediated canonical NFκB signalling in macrophages, whereas mouse
embryonic fibroblasts, murine dermal fibroblasts, and keratinocytes required TRAF2, but not SK-1, for
full strength TNF signalling and NFκB activation.
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The role of Spns2 in inflammation is slowly beginning to emerge. Mainly the fact that blood S1P
levels are reduced by 40% in Spns2-deficient mice [16] and that these mice are lymphopenic suggests
that T lymphocyte-driven inflammatory and autoimmune diseases can in principle be reduced by
Spns2 downregulation or inhibition. Indeed, it was recently shown that Spns2-deficient mice are
protected in an airway inflammation and hypersensitivity model as well as in models of colitis, arthritis,
and experimental autoimmune encephalomyelitis [19]. Interestingly, Sato et al. [53] recently reported
that in patients with advanced liver fibrosis, mRNA expression of Spns2 was enhanced and correlated
with serum alanine aminotransferase (ALT) levels. This upregulated Spns2 in liver fibrosis may result
in enhanced S1P secretion and enhanced autocrine or paracrine action via S1P receptors to stimulate
the fibrotic process.
S1P has been suggested to be critically involved in various models of acute tubular injury. In this
regard, ischemia/reperfusion-induced liver injury in mice that leads not only to liver injury, but
also to acute kidney injury, was accompanied by a reduction of plasma S1P and dihydro-S1P levels,
and application of either S1P or dihydro-S1P acting through S1P1 was shown to reduce systemic
inflammation and protect mice from liver and kidney injury [54,55]. Furthermore, in a mouse model
of cisplatin-induced tubular injury, S1P and FTY720, via S1P1 activation, reduced acute kidney
injury [56], which was suggested to be due to a stabilizing role of S1P1 in tubular mitochondrial
function. Very recently, it was reported that SK-2 deficient mice develop less kidney fibrosis due
to increased interferon (IFN)-γ production [57]. How exactly the loss of SK-2 leads to increased
INFγ production was not further investigated. Similar data were also shown by Schwalm et al. [58]
who demonstrated a protective effect of SK-2 deficiency in unilateral ureter-induced kidney fibrosis,
which was mediated by the upregulation of the anti-fibrotic Smad7 in kidney tissue, but also seen in
isolated SK-2-deficient renal fibroblasts and in SK-2 knockdown HK2 cells. Notably, SK-2-deficient
mice are known to have increased S1P levels in the plasma [59] and in certain organs and cellular
systems [60,61]. It is therefore tempting to speculate that the increased S1P, either intracellularly or
extracellularly, somehow contributes to the protective effect. Furthermore, it was reported that nuclear
S1P, as provided by SK-2, could inhibit HDAC activity [6], and HDAC inhibitors are known to reduce
renal fibrosis [62]. Thus, it is possible that such a mechanism accounts for the protective effect seen in
SK-2 deficient mice that are exposed to ureter ligation-induced interstitial fibrosis [57].
Our data also demonstrate for the first time that Spns2kd HK2 cells express higher levels of AQP1
mRNA and that AQP1 is decreased under inflammatory conditions, which is normalized by Spns2kd
(Figure 9A). The proximal tubulus is highly equipped with multiple channels and transporters that are
crucial for the physiological function of the renal tubulus, which includes the reabsorption of solutes,
peptides, ions, and water. About 60% of the glomerular filtrate water reabsorption is handled by the
proximal tubular system, and this is mainly driven by AQP1, which is abundantly expressed at this
site. In many forms of renal disease, a reduced water reabsorption in the kidney is manifested, which
correlates with reduced expression of various AQPs, including AQP1 [24,25], and AQP1-deficient
mice typically show polyuria as they are unable to concentrate their primary urine [63]. Interestingly,
these AQP1-deficient mice showed increased LPS-induced renal injury [64]. Additionally, it is worth
noting that in LPS-induced sepsis in mice, plasma S1P levels are reduced [65,66]. These studies may
indeed suggest an inverse correlation between the two effector molecules S1P and AQP1 and disease
severity in systemic inflammation. So far, little is known about the transcriptional regulation of
AQP1. It was previously shown to be transcriptionally upregulated by transferrin, which is a known
proteinuric component perturbing tubular function [67], by D-glucose [68], hypertonic stress [69],
and by PPARγ [68]. In addition, AQP1 transcription was shown to be regulated by the transcription
factor MEF2c and Sp1 in endothelial cells, and to contribute to endothelial cell migration and tube
formation [70]. Notably, S1P was also shown to increase the expression of MEF2c in cardiac progenitor
cells [71], which makes it tempting to speculate that S1P regulates AQP1 via MEF2c as a general
mechanism. How this is regulated in HK2 cells remains to be investigated.
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Altogether, our data demonstrate that Spns2 and S1P have a crucial effect on proximal tubular
epithelial cells by regulating an inflammatory process and a subsequent fibrotic reaction, and also by
influencing other tubular transporters that are involved in the pathophysiology of inflammatory and
fibrotic kidney diseases. We conclude that Spns2 represents a promising pharmacological target to
treat these pathological conditions.
4. Materials and Methods
4.1. Chemicals
S1P and all C17-sphingolipid standards were from Avanti Polar Lipids Inc. (Alabaster, AL,
USA); caged-S1P was from Enzo Life Sciences Inc. (Farmingdale, NY, USA); human TGF-β2,
TNFα, and IL-1β were from Peprotech (London, UK); BAF312 was from Selleck Chemicals Inc.
(Houston, TX, USA); CYM5442, CYM5520, CYM5541, puromycin, the lentiviral particles of human
Spns2 and SK-1 shRNA constructs (MISSION® shRNA), diamidine-phenylindole (DAPI), and the
antibodies against α-tubulin and Spns2 (SAB2104271) were from Sigma Aldrich Chemikalien, (Buchs,
Switzerland); antibodies against phospho-ERK1/2, phospho-Smad2, and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) were from Cell Signaling Technology (Danvers, MA, USA); antibodies
against CTGF (L-20) and fibronectin (EP5) were from Santa Cruz (Heidelberg, Germany); the AQP1
antibody (EPR11588(B)) was from Abcam plc (Cambridge, UK); the human SK-1 antibody was
generated and characterized, as previously described [72,73]. The secondary anti-rabbit and anti-mouse
horseradish peroxidase-coupled IgG antibodies and the enhanced chemiluminescence (ECL) reagents
were from GE Health Care Systems GmbH (Freiburg, Germany). The human MCP-1 ELISA was from
Boster Biological Technology (Pleasanton, CA, USA). All of the cell culture nutrients were from Life
Technologies AG (Basel, Switzerland).
4.2. Cell Culture and Transfections
The human renal proximal tubular epithelial cell line HK2 (ATCC, American Type Culture
Collection, Manassas, VA, USA) was cultured in DMEM/F-12 medium that was supplemented with
10% fetal bovine serum (FBS), 100 units/mL penicillin, and 100 µg/mL streptomycin at 37 ◦C in 5%
CO2 atmosphere. Prior to stimulation, cells were serum starved by incubation for 16 h in Dulbecco’s
modified Eagle medium (DMEM) including 0.1 mg/mL of fatty acid-free bovine serum albumin (BSA)
and penicillin/streptomycin. For Spns2 knockdown experiments, 1% FBS was added to the starving
medium. For stable gene silencing of SK-1 (SK-1kd) and Spns2 (Spns2kd), commercially available
short hairpin RNA (shRNA) lentiviral transduction particles (MISSIONR) were used. Transduction
of HK2 cells was performed, according to the manufacturer’s instructions. SK-1kd HK2 cells were
generated with lentiviral transduction particles, as previously described [74]. For Spns2kd HK2 cells,
five different shRNA constructs were tested and the clone showing the strongest downregulation of
Spns2 expression was used for further experiments. For stable selection, 1 µg/mL puromycin was
included in the medium. For Spns2 overexpression, a GFP-fused cDNA of Spns2 (kindly provided
by Dr. A. Kawahara, National Cardiovascular Center Research Institute, Osaka, Japan, [75]) was
transiently transfected in HK2 wildtype cells using lipofectamin, as recommended by the manufacturer
(Thermo Fisher Scientific Inc., Waltham, MA, USA) 48 h post transfection, cells were subcultured and
taken for experiments or characterization of successful transfection by confocal microscopy. Chinese
hamster ovary cells (CHO-S1P3) were kindly provided by Dr. D. Guerini (Novartis Pharma Inc., Basel,
Switzerland) and cultivated in RPMI 1640 supplemented with 10% FBS, 50 µg/mL gentamycin and 0.5
mg/mL G418.
4.3. Western Blot Analysis
From stimulated cells the medium was collected for protein precipitation by adding trichloroacetic
acid (TCA) up to a final concentration of 7% (w/v). Samples were incubated for 30 min at 4 ◦C and were
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centrifuged for 30 min at 13,000× g. Precipitated proteins were redissolved in SDS-Laemmli buffer
and were taken for protein separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), protein transfer to nitrocellulose membrane, and Western blotting. Cell monolayers
were washed once with ice-cold phosphate-buffered saline (PBS) solution. Thereafter, cells were
scraped into ice-cold lysis buffer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton
X-100, 2 mM EDTA, 2 mM EGTA, 40 mM β-glycerophosphate, 50 mM sodium fluoride, 10 mM
sodium pyrophosphate, 2 mM DL-dithiothreitol, 200 µM sodium orthovanadate, 10 µg/mL leupeptin,
10 µg/mL pepstatin A, and 1 mM phenylmethyl sulphonyl fluoride) and were homogenized by
sonication. The samples were then centrifuged for 10 min at 13,000× g and the supernatant was taken
for protein determination. Cell lysates containing equal amounts of protein (35 µg) were separated
by SDS-PAGE, transferred to nitrocellulose membrane for 1 h at 250 mA using a Transblot apparatus
(Bio-Rad Laboratories GmbH, München, Germany). The blotting buffer used was 25 mM Tris, 190 mM
glycine and 20% MeOH (v/v). After transfer, the nitrocellulose membranes were washed in distilled
water and were blocked in blocking buffer containing 3% (w/v) low-fat milk powder in PBS for 1 h
at 25 ◦C. Membranes were then incubated with the indicated antibodies overnight at 4 ◦C on a plate
shaker. All of the antibodies were diluted in 50 mM Tris/HCl pH 7.4, 200 mM NaCl, 10% horse serum,
3% (w/v) BSA fraction V, 0.1% (v/v) Tween-20. Thereafter, membranes were washed 3 × 10 min in
buffer containing 50 mM Tris/HCl pH 7.4, 200 mM NaCl, 0.2% (v/v) Triton X-100 and incubated
with secondary antibodies for 1 h at 25 ◦C, washed 3 × 10 min, and then incubated with enhanced
chemiluminescence (ECL) reagents, according to the manufacturers recommendations. For fibronectin
transfer to nitrocellulose, 0.1% (w/v) SDS was added to the transfer buffer.
4.4. Quantitative Real-Time PCR Analysis (qPCR)
qPCR was performed using SYBRGreenR and a Bio-Rad iQ iCycler Detection System. Primers
were as follows: human SK-1: forward: 5′-GCT TCC TTG AAC CAT TAT G-3′; reverse: 5′-TCT CTA
GGT CCA CAT CAG-3′; human CTGF: forward: 5′-TGC CTG CCA TTA CAA CTG TCC-3′, reverse:
5′-GCC ATG TCT CCG TAC ATC TTC C-3′; human fibronectin: forward: 5′-CGA AAT CAC AGC CAG
TAG-3′; reverse: 5′-ATC ACA TCC ACA CGG TAG-3′; human Spns2: forward: 5′-ACT TTG GGG TCA
AGG ACC GA-3′; reverse: 5′-AAT CAC CTT CCT GTT GAA GCG-3′; human MCP-1: forward: 5′-CCC
CAG TCA CCT GCT GTT AT-3′; reverse: 5′-TGG AAT CCT GAA CCC ACT TC-3′; human aquaporin
1: forward: 5′-TGG ACA CCT CCT GGC TAT TG-3′; reverse: 5′-GGG CCA GGA TGA AGT CGT
AG-3′; 18S RNA: forward: 5′-CGA TTC CGT GGG TGG TGG TG-3′; reverse: 5′-CAT GCC AGA GTC
TCG TTC GTT ATC-3′. 1 µg of total RNA isolated with TRIzolR (Thermo Fisher Scientific) reagent was
used for reverse transcriptase cDNA synthesis (First Strand Synthesis Kit, Thermo Fisher Scientific); a
random hexamer primer was used for amplification. Real-time fluorescence from SYBRR Green (Sigma
Aldrich) was measured by the Bio-Rad CFX Manager 3.1 System Software. The fold induction values
were obtained, according to the ∆∆Ct method, after normalization to the housekeeping gene 18S RNA.
4.5. Determination of S1P Generation and Secretion by a Reporter Assay
HK2 cells were seeded onto 12-well plates and stimulated, as described in DMEM supplemented
with 10 mg/mL of BSA. In parallel, the cells in additional wells were counted to determine cell
number. After stimulation, HK2 cell monolayers were washed once with ice-cold PBS, scraped
into PBS containing 10 mg/mL BSA and homogenized by sonication. Samples were centrifuged
for 10 min at 13,000× g at 4 ◦C and the supernatant was stored at −80 ◦C for further CHO-S1P3
cell stimulations to determine iS1P concentrations. In addition, media from stimulated HK2 cells
were collected, centrifuged for 5 min at 1500× g at 4 ◦C, and the supernatants were collected for
further CHO-S1P3 stimulation using 10% (v/v) of the conditioned medium in fresh DMEM. Prior to
stimulation, CHO-S1P3 cells were starved for 22 h in serum-free DMEM, including 0.1 mg/mL of fatty
acid-free BSA and then stimulated for 10 min with either DMEM containing the HK2 lysate (5000 cell
equivalents per mL), or with 10% (v/v) HK2 conditioned medium. Thereafter, CHO-S1P3 cells were
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washed with PBS and then harvested for Western blotting to determine ERK phosphorylation as a
read-out for receptor activation.
4.6. Quantification of S1P by Mass Spectrometry
Cell monolayers in 35 mm-diameter dishes were trypsinized, pelleted and stored at −80 ◦C
until further processing. Samples were resuspended in methanol containing internal C17-ceramide,
C17-sphingosine, and C17-S1P standards, and were subjected to lipid extraction and LC/MS/MS
analysis, as previously described [76].
4.7. Statistical Analysis
Statistical analysis was performed by one-way analysis of variance (ANOVA). For multiple
comparisons with the same control group, the limit of significance was divided by the number of
comparisons, according to Bonferroni.
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AQP aquaporin
BSA bovine serum albumin
CHO cells Chinese hamster ovary cells
CTGF connective tissue growth factor
DMEM Dulbecco’s modified Eagle medium
ECL enhanced chemiluminescence
ERK extracellular signal regulated kinase
eS1P extracellular sphingosine 1-phosphate
FBS fetal bovine serum
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GFP green fluorescence protein
HDAC histone deacetylase
HK2 human proximal tubular epithelial cells
IFN interferon
IL interleukin
iS1P intracellular S1P
kd knockdown
MCP-1/CCL2 monocyte chemoattractant peptide 1
MFS major facilitator superfamily
NFκB nuclear factor κB
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
shRNA small hairpin RNA
SK sphingosine kinase
Spns2 spinster homology protein 2
TGFβ transforming growth factor β
TNFα tumor necrosis factor α
TRAF2 TNF receptor-associated factor 2
UUO unilateral ureter obstruction
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